Stocks and Investing
Stocks and Investing
Tue, October 26, 2021
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Salim Syed Maintained (BIIB) at Hold with Decreased Target to $270 on, Oct 26th, 2021
Salim Syed of Mizuho, Maintained "Biogen Inc." (BIIB) at Hold with Decreased Target from $300 to $270 on, Oct 26th, 2021.
Salim has made no other calls on BIIB in the last 4 months.
There are 11 other peers that have a rating on BIIB. Out of the 11 peers that are also analyzing BIIB, 3 agree with Salim's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Brian Abrahams of "RBC Capital" Maintained at Hold with Decreased Target to $295 on, Thursday, October 21st, 2021
- Alethia Young of "Cantor Fitzgerald" Maintained at Hold with Decreased Target to $327 on, Friday, October 15th, 2021
- Carter Gould of "Barclays" Maintained at Hold with Decreased Target to $290 on, Friday, October 8th, 2021
These are the ratings of the 8 analyists that currently disagree with Salim
- Ami Fadia of "Needham" Maintained at Strong Buy with Decreased Target to $386 on, Thursday, October 21st, 2021
- Jay Olson of "Oppenheimer" Maintained at Buy with Decreased Target to $390 on, Thursday, October 21st, 2021
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $440 on, Thursday, October 21st, 2021
- Phil Nadeau of "Cowen & Co." Maintained at Buy with Decreased Target to $375 on, Thursday, October 21st, 2021
- Paul Matteis of "Stifel" Maintained at Strong Buy with Decreased Target to $344 on, Friday, October 15th, 2021
- Michael Yee of "Jefferies" Maintained at Strong Buy with Decreased Target to $400 on, Friday, October 8th, 2021
- Colin Bristow of "UBS" Maintained at Strong Buy with Decreased Target to $442 on, Thursday, September 16th, 2021
- Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $423 on, Tuesday, July 27th, 2021
Contributing Sources